Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Amendment after Non-final office action filed on September 1, 2026, is acknowledged.
New claims 11-17 have been added.
Claims 1-17 are pending in this application.
Applicant elected Group 1 (claims 1-6) in the reply filed on May 1, 2026. Because Applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP 818.01(a)). The restriction was deemed to be proper and was made FINAL in the previous office action. Claims 7-10 remain withdrawn from consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim. Claims 1-6 and 11-17 are examined on the merits in this office action.
This application contains claims 7-10, drawn to an invention nonelected without traverse in the paper of 5/1/2026. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144). See MPEP § 821.01.
Withdrawn Objections and Rejections
Objection to the abstract is hereby withdrawn in view of Applicant’s amendment to the abstract.
Objection to the drawing is hereby withdrawn in view of Applicant’s filing replacement sheet on 9/1/2026.
Objection to the specification is hereby withdrawn in view of Applicant’s amendment to the specification.
Rejection of claims 1 and 5-6 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, for reciting the term “preferably”, is hereby withdrawn in view of Applicant’s amendment to the claims.
Rejection of claim 1 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is hereby withdrawn in view of Applicant’s amendment to the claim.
Rejection of claim 1 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is hereby withdrawn in view of Applicant’s amendment to the claim.
Please note, the specification has not been checked to the extent necessary to determine the presence of all possible error. Applicant's cooperation is required in correcting any errors of which applicant may become aware in the specification. MPEP § 608.01.
Maintained Rejections
35 U.S.C. 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-6 and 11-17 remain/are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. This rejection is maintained and revised in view of Applicant’s amendment to the claims.
Claims 1-6 and 11-17 recite a product and a method of making the product. A claim can only recite one invention. The metes and bounds of the claims are unclear because it is unclear if the claims are drawn to a product or a method invention. Because the preamble recites “Amino acid-based biomolecular glass”, the claims are interpreted as being a product invention.
Response to Applicant’s Arguments
Applicant did not respond to this rejection. Therefore, the rejection is deemed to be proper and is maintained herein.
35 U.S.C. 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1-3, 5-6 and 11-17 remain/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Knight reference (US 2007/0087024, cited in the previous office action). This rejection is maintained and revised in view of Applicant’s amendment to the claims.
Knight reference teaches a matrix made from a glassy protein, that includes serine (see abstract, for example). Knight reference teaches the 8 residue peptide sequence SSNTDSNS (SEQ ID NO: 1) that meets the limitation of a peptide of no less than 2 of instant claims 1-3 and 13, and no more than 10 of instant claim 13. In regards to instant claims 5-6 and 11-17, because Knight reference teaches a glassy protein matrix material made up of amino acids/peptides, the glassy protein matrix material would inherently have all of the activity and functionality as instant amino acid-based biomolecular glass. The MPEP 2112 states: “Once a reference teaching product appearing to be substantially identical is made the basis of a rejection, and the Examiner presents evidence or reasoning tending to show inherency, the burden shifts to the Applicant to show an unobvious difference “[t]he PTO can require an Applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his[or her] claimed product. Whether the rejection is based on inherency’ under 35 U.S.C. 102, on prima facie obviousness’ under 35 U.S.C. 103, jointly or alternatively, the burden of proof is the same…[footnote omitted].” The burden of proof is similar to that required with respect to product-by-process claims. In re Fitzgerald, 619 F.2d 67, 70, 205 USPQ 594, 596 (CCPA 1980) (quoting In re Best, 562 FR.2d 1252, 1255, 195 USPQ 430, 433-34 (CCPA 1977)).” Since Knight reference teaches All of the active components, the Knight reference anticipates instant claims 1-3, 5-6 and 11-17.
Response to Applicant’s Arguments
Applicant argues that “The term “glass” in the present application is in a broad sense and refers to a glassy substance possessing properties similar to those of inorganic glass. The subject matter of claim 1 has been amended to “amino acid-based biomolecular glass” to emphasize the organic nature of the claimed glass. Knight (US 2007/0087024) describes a glassy protein containing at least 5 mol% serine and discloses the examples that the glass transition temperature of dried serine protein is 88C…” Applicant further argues that “Knight contains no disclosure or suggestion regarding the “transparency” of the glass…Furthermore, the amino acid-based biomolecular glass of the present application exhibits a transparency of 30% or more, while the prior art does not disclose, teach, or suggest such a biomolecular glass or preparation method thereof…”
Applicant’s arguments have been fully considered but are not found persuasive. Knight reference explicitly teaches a matrix made from a glassy protein, that includes serine and teaches the 8 residue peptide sequence SSNTDSNS (SEQ ID NO: 1). A peptide is an organic material, therefore, it would be a biomolecular glass, meeting the limitation of “Amino acid-based biomolecular glass”. Furthermore, the glassy protein matrix made up of SSNTDSNS, for example, would inherently have ALL of the functionality and activity of instant amino acid-based biomolecular glass. Additionally, the MPEP 2112.01 II states that “Products of identical chemical composition cannot have mutually exclusive properties.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical structure, the properties applicant discloses and/or claims are necessarily present. Id”.
Therefore, the rejection is deemed to be proper and is maintained herein.
35 U.S.C. 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 1-6 and 11-17 remain/are rejected under 35 U.S.C. 103 as being unpatentable over Knight reference (US 2007/0087024, cited in the previous office action) in view of Xu reference (CN 107673599, filed with IDS, Google patent English translation used and enclosed in the previous office action). This rejection is maintained and revised in view of Applicant’s amendment to the claims.
Knight reference teaches a matrix made from a glassy protein, that includes serine (see abstract, for example). Knight reference teaches the 8 residue peptide sequence SSNTDSNS (SEQ ID NO: 1) that meets the limitation of a peptide of no less than 2 of instant claims 1-3 and 13, and no more than 10 of instant claim 13. In regards to instant claims 5-6 and 11-17, because Knight reference teaches a glassy protein matrix material made up of amino acids/peptides, the glassy protein matrix material would inherently have all of the activity and functionality as instant amino acid-based biomolecular glass. The MPEP 2112 states: “Once a reference teaching product appearing to be substantially identical is made the basis of a rejection, and the Examiner presents evidence or reasoning tending to show inherency, the burden shifts to the Applicant to show an unobvious difference “[t]he PTO can require an Applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his[or her] claimed product. Whether the rejection is based on inherency’ under 35 U.S.C. 102, on prima facie obviousness’ under 35 U.S.C. 103, jointly or alternatively, the burden of proof is the same…[footnote omitted].” The burden of proof is similar to that required with respect to product-by-process claims. In re Fitzgerald, 619 F.2d 67, 70, 205 USPQ 594, 596 (CCPA 1980) (quoting In re Best, 562 FR.2d 1252, 1255, 195 USPQ 430, 433-34 (CCPA 1977)).” Since Knight reference teaches All of the active components, the Knight reference anticipates instant claims 1-3, 5-6 and 11-17.
The difference between the Knight reference and the instant claims is that the Knight reference does not teach additional raw materials such as clarifiers, fluxes, opacifiers and colorants.
However, Xu reference teaches non-lead glass, lead-free glass mainly comprises nitrate, clarifier silicon, dioxide, amino acid and nanometer zinc oxide…the amino acid accounts for 17-19 parts of overall component (see abstract and claim 1). Xu reference further teach other components such as decolorizing agent (see claim 5) and fluorescent brightening agent (see claim 7). Xu reference teaches:
PNG
media_image1.png
86
740
media_image1.png
Greyscale
(see p. 2, 1st full paragraph).
Therefore, it would have been obvious to one of ordinary skill in the art to combine the teachings of Knight and Xu to arrive at amino acid based glass having additional raw material such as colorants and clarifiers because both references teach peptide based glass. One of ordinary skill in the art would be motivated to combine with a reasonable expectation of success, since Xu reference teaches that colored glaze add quality and glitter and translucent, bright and glittering changes to the glass, and that color and clarifiers can be added to enhance amino acid based glass. Therefore, the combined art is prima facie obvious over instant claims 1-6 and 11-17.
Response to Applicant’s Arguments
Applicant argues that “The term “glass” in the present application is in a broad sense and refers to a glassy substance possessing properties similar to those of inorganic glass. The subject matter of claim 1 has been amended to “amino acid-based biomolecular glass” to emphasize the organic nature of the claimed glass. Knight (US 2007/0087024) describes a glassy protein containing at least 5 mol% serine and discloses the examples that the glass transition temperature of dried serine protein is 88C…” Applicant further argues that “Knight contains no disclosure or suggestion regarding the “transparency” of the glass…Furthermore, the amino acid-based biomolecular glass of the present application exhibits a transparency of 30% or more, while the prior art does not disclose, teach, or suggest such a biomolecular glass or preparation method thereof…” Applicant argues that “Xu teaches non-lead glass and further teaches other components such as decolorizing agents and fluorescent brightening agent. Xu fails to overcome the above defects of Knight.”
Applicant’s arguments have been fully considered but are not found persuasive. As indicated in the response above, Knight reference explicitly teaches a matrix made from a glassy protein, that includes serine and teaches the 8 residue peptide sequence SSNTDSNS (SEQ ID NO: 1). A peptide is an organic material, therefore, it would be a biomolecular glass, meeting the limitation of “Amino acid-based biomolecular glass”. Furthermore, the glassy protein matrix made up of SSNTDSNS, for example, would inherently have ALL of the functionality and activity of instant amino acid-based biomolecular glass. Additionally, the MPEP 2112.01 II states that “Products of identical chemical composition cannot have mutually exclusive properties.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical structure, the properties applicant discloses and/or claims are necessarily present. Id”.
The Xu reference explicitly teaches other components that can be added to peptide glass materials. One of ordinary skill in the art would be motivated to combine with a reasonable expectation of success, since Xu reference teaches that colored glaze add quality and glitter and translucent, bright and glittering changes to the glass, and that color and clarifiers can be added to enhance amino acid based glass. In response to applicant’s argument that there is no teaching, suggestion, or motivation to combine the references, the examiner recognizes that obviousness may be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See In re Fine, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988), In re Jones, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992), and KSR International Co. v. Teleflex, Inc., 550 U.S. 398, 82 USPQ2d 1385 (2007). In this case, the other components (auxiliary raw materials) added to the glass may add different aesthetic quality or component to the amino acid-based biomolecular glass..
Therefore, the rejection is deemed to be proper and is maintained herein.
New Objections
Claims 11-16 are objected to for the following: Claims 11-16 recite, “Amino acid-based biomolecular…” Claims 11-16 are missing the article “The”. For example, claim 11 should be amended to recite, “The amino acid-based biomolecular glass…”
New Rejections
DOUBLE PATENTING
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-6 and 11-17 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of copending Application No19/480541 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because if one of ordinary skill in the art practiced the claimed invention of instant claims, one would necessarily achieve the claimed invention of copending claims and vice versa.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Instant claims are drawn to:
PNG
media_image2.png
616
580
media_image2.png
Greyscale
.
Copending claims are drawn to:
PNG
media_image3.png
132
572
media_image3.png
Greyscale
.
Instant claims and copending claims recite a biomolecular glass , the biomolecular glass comprising natural amino acid or a peptide or an amino acid derivative or a peptide derivative. Instant claims and copending claims share a similar scope. Therefore, if one of ordinary skill in the art practiced the claimed invention of instant claims, one would necessarily achieve the claimed invention of copending claims, and vice versa.
CONCLUSION
No claim is allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JULIE HA whose telephone number is (571)272-5982. The examiner can normally be reached Monday-Thursday 5:00 am- 6:30 pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, LIANKO GARYU can be reached at 571-270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JULIE HA/Primary Examiner, Art Unit 1654
11/10/2026